



India financials

Sector outlook

Adarsh Parasrampuria

adarsh.parasrampuria@clsa.com +91 22 6650 5057

Mohit Surana

+91 22 6650 5037

Piran Engineer

+91 22 6650 5006

Shreya Shivani


+91 22 6650 5056

26 January 2023

India

Financial services


Breakdown of top 5 group companies' debt:



Total debt doubled in past 4 years:



Breakdown of incremental debt (FY19-22):



Adani - Where does the debt sit?

Exposure of private banks very low

In this report, we examine banks' exposure to Adani group debt. The key message is that Indian banking exposure is less than 40% of total group debt. Within this, private banks' exposure is below 10% of total group debt and most banks (including ICICI/Axis) have indicated that they have largely financed assets with strong cashflows, such as airports/ports. PSU banks do have material exposure (30% of group debt) but this debt has not increased in the past three years. Most of the incremental funding to the group for new businesses and acquisitions has come via overseas sources. To conclude, the ballpark exposure of private banks is 0.3% of FY24 loans and 1.5% of FY24 networth. For PSU banks, the exposure is 0.7% of FY24 loans and 6% of FY24 networth.

Aggregate debt of top 5 Adani group companies

- We aggregate the consolidated debt of the top-5 Adani group companies: Adani Enterprises, Adani Ports, Adani Power, Adani Green and Adani Transmission.
- □ While there may be some element of double counting in group debt, we calculate consolidated debt of Rs2.1tn for these companies; excluding inter-group lending, the debt is Rs1.9tn.
- ☐ Bank debt (term loans, working capital and other facilities) forms just 38% of the total debt, while bonds/CP constitute 37%, 11% is borrowing from financial institutions and the remaining 12-13% is inter-group lending.
- □ On an absolute level, we estimate that bank debt is Rs700-800bn of the Rs2tn debt in FY22. While debt levels have doubled from Rs1tn to Rs2tn in the past three years, bank debt has increased by more than 25%. The share of bank debt in overall group debt has reduced materially and we estimate that incrementally banks have only lent Rs150bn, or 15% of the Rs1tn the group companies have borrowed over the past three years.
- Large acquisitions, such as cement, have been fully funded by foreign banks (Figure 11).

Company data corroborates lower share of bank lending especially private banks

- Adani Group's debt disclosures corroborate our findings of a declining share of bank funding in Adani's overall debt mix.
- The group has indicated that the share of PSU banks in its funding mix has dropped from 55% in FY16 to 26% now while the share of private banks has plunged from 31% to 8%. A greater part of the group's funding now comes from bonds at 37% (funding ports and the transmission business) and from foreign banks (18% of debt).
- We are broadly able to corroborate our analysis with the company data, indicating that banks are funding 35-40% of Adani Group debt with private banks funding less than 10% and PSU banks funding 25-30% of the debt.

Exposure levels manageable – very little risk for private banks

- ☐ In Figure 9, we estimate that banking exposure to Adani Group is 0.55% of system loans as bank debt stands at less than 40% of total group borrowing. Within this, PSU banks' exposure as a share of their loans is 0.7%, with the figures for some banks potentially at more than 1% of loans, while for private banks the exposure is 0.3% of loans.
- ☐ For private banks, our feedback suggests that they have potentially reduced their exposure on aggregate and the residual debt to the group is largely in very strong cashflow businesses, such as power and airports. We estimate the absolute exposure at 1.4% of private banks' FY24 networth - any weakness due to concerns over the group's debt would provide an opportunity to BUY, in our opinion.
- For PSU banks, the exposure is more meaningful at 0.6% of loans and 5% of FY24 networth. PSU banks have also indicated that their exposure has not meaningfully increased in the past two to three years since the group has expanded into new businesses. Also, most of the recent acquisitions have been financing by foreign entities. One caveat is that we are not aware of non-funded exposures that PSU banks might have extended.






www.clsa.com

Adani group - Where does the debt sit?

igure 1

Adani Group structure – we take a closer look at debt for the larger group companies on the left in the chart below





(%): Promoter equity stake in Adani Portfolio companies (%): AEL equity stake in its subsidiaries

1. Combined market cap of all listed entities as on July 31, 2022, USD/INR – 79.34 | 2. NQXT: North Queensland Export Terminal | 3. ATGL: Adani Total Gas Ltd, JV with Total Energies | 4. Data center, JV with EdgeConnex, AEL: Adani Enterprises Limited; APSEZ: Adani Ports and Special Economic Zone Limited; ATL: Adani Transmission Limited; TDD: Transmission & Distribution; APL: Adani Power Limited; AGEL: Adani Green Energy Limited; AAHL: Adani Airport Holdings Limited; ARTL: Adani Roads Transport Limited; ANIL: Adani New Industries Limited; AWL: Adani Wilmar Limited; ADL: Adani Digital Limited; IPP: Independent Power Producer

Source: Company data

Figure 2

Debt of the top-5/6 companies of Adani Group – Rs1.9tn excluding inter-group lending								
Rsm	Adani Power	Adani Green	Adani Ports	Adani Enterprises	Adani Transmission	Top-5 Adani		
Bank debt	323,284	206,640	51,828	179,445	51,149	812,347		
Bonds								
Rupee	-	6,000	93,733	68,405	1,109	169,246		
USD/others	-	118,880	302,099	-	197,393	618,372		
Borrowing from fin. Inst.	82,650	107,620	-	28,819	24,367	243,456		
Related party + incorporate	65,014	30	-	88,673	23,235	176,952		
Others	7,216	37,820	-	44,895	-	89,931		
Total	478,164	476,990	447,660	410,238	297,253	2,110,304		
Total (ex-RPT/IC debt)	413,150	476,960	447,660	321,565	274,018	1,933,352		


Source: Companies, CLSA

Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com



Our bottom up analysis ties in well with the group's disclosures

Our estimate of the where the debt sits - <40% with the banks



Source: Companies, CLSA

Figure 3

Figure 4

Debt levels over the past four years


Rsbn ■Top 5 companies' total debt - Adani Group 2,500 2,110 2,000 2× 1.471 1,361 1,500 1,150 1,000 500 0 **FY19** FY20 FY21 FY22

Source: Companies, CLSA

Figure 5

Small part of the debt increase funded by banks in past three years






Source: Companies, CLSA

Share of bank funding in overall Adani Group debt has come down from 86% in FY16 to less than 40% in FY22

Figure 6

Company data also indicate similar trends (%)



Source: Companies, CLSA



Debt of the top Adani

companies has increased from Rs1tn to Rs2tn over the past three to four years

Within this, bank funding is less than 40%, we estimate, while bonds, financial institutions and foreign banks form a larger part of the group debt

Figure 8

Bank funding to the group has not materially increased in the past few years

Private banks' exposure

quite low at below 2% of

net worth

Figure 7

Group level debt by source based on Adani companies' annual reports								
Adani Group debt	Power	Green	Ports	Enterprises	Transmission	Total (Top-5)		
Total debt (Rsbn)	478	477	448	410	297	2,110		
Bank debt	323	207	52	179	51	812		
Rupee bonds	-	6	94	68	1	169		
USD/FX bonds	-	119	302	-	197	618		
Borrowing from fin. Inst.	83	108	-	29	24	243		
Related party + incorporate	65	0	-	89	23	177		
Others	7	38	-	45	-	90		
Composition								
Bank debt	68%	43%	12%	44%	17%	38%		
Rupee bonds	0%	1%	21%	17%	0%	8%		
USD/FX bonds	0%	25%	67%	0%	66%	29%		
Borrowing from fin. Inst.	17%	23%	0%	7%	8%	12%		
Related party + incorporate	14%	0%	0%	22%	8%	8%		
Others	2%	8%	0%	11%	0%	4%		

Source: Companies, CLSA

Group debt movement over past three to four years								
Top 5 cos' agg. debt (Rsbn)	FY19	FY20	FY21	FY22				
Bank debt	661	540	543	812				
Rupee bonds	148	68	94	169				
USD/FX bonds	151	424	461	618				
Borrowing from fin. Inst.	72	140	189	243				
Related party + incorporate	53	81	142	177				
Others	65	108	40	90				
Total	1,150	1,361	1,471	2,110				
Total (ex-RPT/IC debt)	1,097	1,281	1,329	1,933				
Bank debt	57%	40%	37%	38%				
Rupee bonds	13%	5%	6%	8%				
USD/FX bonds	13%	31%	31%	29%				
Borrowing from fin. Inst.	6%	10%	13%	12%				
Related party + incorporate	5%	6%	10%	8%				
Others	6%	8%	3%	4%				

Source: Companies, CLSA

Figure 9

Exposu

Exposure of private banks is quite low			
Rsbn	PSU banks	Private banks	Total banks
Adani exposure (estimate)	550	175	725
% of Adani Group debt	28.6%	9.5%	38.1%
FY22 loans	70,000	45,000	115,000
FY24 loans - estimate	87,745	60,030	147,775
Exposure (% of FY24 loans)	0.63%	0.29%	0.49%
FY22 net worth (ex revaluation reserves)	7,300	8,300	15,600
FY24 net worth (ex revaluation reserves)	9,404	10,977	20,381
Exposure (% of FY24 net worth)	5.8%	1.6%	3.6%
Exposure (% of FY24 net worth - post tax)	4.4%	1.2%	2.7%

Source: Companies, banks, RBI, CLSA



Aggregate debt levels have improved over the years

Figure 10

Leverage levels of Adani Group companies (aggregate of top five companies)								
Rsm	FY17	FY18	FY19	FY20	FY21	FY22		
Adani Group								
Debt	1,082,305	1,121,304	1,200,976	1,274,406	1,519,209	2,119,822		
Net worth	386,451	423,299	454,087	462,527	678,300	903,128		
EBITDA	168,668	166,597	174,815	213,054	282,777	384,280		
Interest	101,058	98,723	112,221	118,810	125,153	141,603		
Dep. & Amort.	53,751	56,734	64,580	67,272	76,610	93,811		
PBT	74,422	101,911	107,837	100,320	103,702	162,225		
Gross Debt/Ebitda	6.42	6.73	6.87	5.98	5.37	5.52		
Ebitda/ interest	1.67	1.69	1.56	1.79	2.26	2.71		

Source: Companies, CLSA

Figure 11

Holcim acquisition financing of Rs420bn entirely by foreign banks

Company disclosure of Holcim funding by overseas banks

Holcim Acquisition						
Underwriter Barclays, DB & SCB – INR 42,000 Cr.						
Underwriter Hold	8,100					
DBS	6,000					
MUFG	4,800					
Intesa	3,600					
SMBC	2,800					
FAB	2,800					
Mizuho & others	13,900					

Source: Companies, CLSA



Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.

Companies mentioned

Adani Airport Holdings (N-R)

Adani Digital (N-R)

Adani Enterprises (N-R)

Adani Green Energy (N-R)

Adani Group (N-R)

Adani New Industries (N-R)

Adani Ports (ADSEZ IB - RS712.9 - O-PF)

Adani Power (N-R)

Adani Road Transport (N-R)

Adani Total Gas (N-R)

Adani Transmission (N-R)

Adani Wilmar (N-R)

AdaniConnex (N-R)

Axis Bank (AXSB IB - RS891.7 - BUY)

Barclays (N-R)

DBS (DBS SP - S\$35.51 - BUY)

EdgeConnex (N-R)

FAB (N-R)

Holcim (N-R)

ICICI Bank (ICICIBC IB - RS855.3 - BUY)

Intesa San (N-R)

Mizuho (N-R)

MUFG (N-R)

North Queensland Export Terminal (N-R)

SMBC (N-R)

Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.











Important disclosures



Date	Rec	Target	Date	Rec	Target
03 Jan 2023	BUY	1,250.00	27 Jul 2021	BUY	1,050.00
25 Nov 2022	BUY	1,200.00	28 Apr 2021	BUY	1,025.00
21 Oct 2022	BUY	1,150.00	28 Jan 2021	BUY	1,000.00
13 Oct 2022	BUY	1,100.00	08 Jan 2021	BUY	850.00
17 Sep 2022	BUY	1,050.00	29 Oct 2020	BUY	700.00
26 Jul 2022	BUY	975.00	22 Jul 2020	BUY	600.00
20 Jun 2022	BUY	900.00	22 Jun 2020	BUY	580.00
29 Apr 2022	BUY	1,040.00	20 Apr 2020	BUY	595.00
27 Oct 2021	BUY	1,080.00			


Source: CLSA



Date	Rec	Target	Date	Rec	Target
12 Oct 2022	BUY	43.40	01 Dec 2020	U-PF	24.60
15 Mar 2022	BUY	41.00	22 Oct 2020	O-PF	23.30
15 Feb 2022	O-PF	41.00	11 Jun 2020	O-PF	24.20
13 Jan 2022	O-PF	38.60	04 May 2020	BUY	24.20
02 Nov 2021	O-PF	36.00	22 Apr 2020	BUY	24.30
03 May 2021	O-PF	31.70	11 Mar 2020	BUY	24.60
10 Feb 2021	O-PF	28.30	05 Feb 2020	O-PF	28.30
01 Feb 2021	O-PF	27.40			


Source: CLSA





Date	Rec	Target	Date	Rec	Target
26 May 2022	O-PF	792.00	08 Feb 2021	BUY	675.00
03 Feb 2022	O-PF	807.00	07 Dec 2020	BUY	540.00
13 Oct 2021	O-PF	825.00	06 Oct 2020	BUY	425.00
04 Aug 2021	O-PF	816.00	10 Jul 2020	O-PF	386.00
05 May 2021	U-PF	816.00	07 May 2020	BUY	386.00
04 Mar 2021	O-PF	770.00	27 Mar 2020	BUY	400.00

Source: CLSA



Date	Rec	Target	Date	Rec	Target
03 Jan 2023	BUY	1,175.00	26 Jul 2021	BUY	940.00
24 Oct 2022	BUY	1,200.00	25 Apr 2021	BUY	825.00
15 Sep 2022	BUY	1,150.00	31 Jan 2021	BUY	800.00
24 Jul 2022	BUY	1,040.00	08 Jan 2021	BUY	675.00
20 Jun 2022	BUY	950.00	07 Dec 2020	BUY	625.00
22 Mar 2022	BUY	1,050.00	02 Nov 2020	BUY	560.00
23 Jan 2022	BUY	1,125.00	27 Jul 2020	BUY	500.00
24 Oct 2021	BUY	1,100.00	22 Jun 2020	BUY	480.00
16 Sep 2021	BUY	1,000.00	20 Apr 2020	BUY	460.00

Source: CLSA

CLSA ("CLSA") in this report refers to CLSA Limited, CLSA Americas, LLC, CLSA Australia Pty Ltd, CLSA India Private Limited, PT CLSA Sekuritas Indonesia, CLSA Securities Japan Co., Ltd., CLSA Securities

Korea Ltd., CLSA Securities Malaysia Sdn. Bhd., CLSA Philippines, Inc, CLSA Singapore Pte Ltd, CLSA Securities (Thailand) Limited, CLSA (UK), CLSA Europe B.V. and/or their respective affiliates. CLST



("CLST") in this report refers to CL Securities Taiwan Co., Ltd.

The policies of CLSA and CLST are to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out hereof and at www.clsa.com/disclaimer.html, the Terms and Conditions of Use as set out at https://www.clsa.com/terms-and-conditions-of-use/ and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members or associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. (For full disclosure of interest for all companies covered by CLSA in this report, please refer to http://www.clsa.com/member/research_disclosures/ for details.)

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's and/or CLST's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF (aka ACCUMULATE): Total expected return below 20% but exceeding market return; U-PF (aka REDUCE): Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

"High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 75.00%, Underperform / SELL - CLSA: 25.00%, Restricted - CLSA: 0.08%; Data as of 1 Jan 2023. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 21.92%, Underperform / SELL - CLSA: 5.08%; Restricted - CLSA: 0.08%. Data for 12-month period ending 1 Jan 2023.

Overall rating distribution for CLST only Universe: Overall rating distribution: BUY / Outperform - CLST: 59.65%, Underperform / SELL - CLST: 40.35%, Restricted - CLST: 0.00%. Data as of 1 Jan 2023. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%,

Restricted - CLST: 0.00%. Data for 12-month period ending 1 Jan 2023.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

Charts and tables sourced to CLSA in this report may include data extracted from CLSA's automated databases, which derive their original data from a range of sources. These can include: companies; analyst estimates/calculations; local exchanges and/or third-party data or market pricing providers such as Bloomberg, FactSet or IBES. Additional information on data sources for specific charts or tables can be obtained by contacting the publishing analysts.

This report is subject to and incorporates the terms and conditions website set out on the www.clsa.com (https://www.clsa.com/disclaimer.html and https://www.clsa.com/terms -and-conditions-of use/) and the references to "publication/communication" or "Publications" thereof shall include this report. Neither this report nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this report for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data (for private or public companies) herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and CLSA and/or CLST makes no representation or warranty as to its fairness, adequacy, accuracy, completeness or correctness. The replication of any third party views in this report should not be treated necessarily as an indication that CLSA and/or CLST agrees with or concurs with such views. None of CLSA and/or CLST, its affiliates and their respective directors, officers, employees, advisers and representatives makes any representation or warranty, express or implied, as to and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such data or information contained herein or any statement made in this report. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this report and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This report is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including



legal or tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to movements of exchange rate. Past performance is not necessarily a guide to future performance or liquidity. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA's Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance department nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details of conflict of interest with companies under coverage are available http://www.clsa.com/member/research_disclosures/. therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company, covered in this report, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com. If you require disclosure information on previous dates, please contact compliance, hk@clsa.com.

Any disputes related to this report sharp be governed by the laws

Any disputes related to this report shall be governed by the laws of Hong Kong and to the non-exclusive jurisdiction of the courts of Hong Kong in connection with any suite, action or proceeding arising out of or in connection with this material. In the event any of the provisions in these Terms of Use shall be held to be unenforceable, that provision shall be enforced to the maximum extent permissible to reflect the intention underlying the unenforceable term, and the remainder of these General Disclaimer shall be unimpaired.

This report is distributed for and on behalf of CLSA (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas, LLC (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992 331/AFSL License No: 350159); in Hong Kong by CLSA Limited (Incorporated in Hong Kong with limited liability); in

India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271: CIN: U67120MH1994PLC083118; Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor" MCI (P) 042/11/2022; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST (for reports compiled by Taiwan analyst(s) or CLSA (for non Taiwan stock reports to CLSA clients) and in the European Economic Area ('EEA") by CLSA Europe BV and in the United Kingdom by CLSA (UK).

Hong Kong: This research report is distributed by CLSA Limited. This research report is distributed in Hong Kong only to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules promulgated thereunder) and may not be distributed to retail investors. Recipients should contact CLSA Limited, Tel: +852 2600 8888 in respect of any matters arising from, or in connection with, the analysis or report.

Australia: CLSA Australia Pty Ltd ("CAPL") (ABN 53 139 992 331/AFS License No: 350159) is regulated by the Australian Securities and Investments Commission ("ASIC") and is a Market Participant of ASX Limited and Cboe Australia Pty Ltd. . This material is issued and distributed by CAPL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party without the prior written consent of CAPL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. CAPL's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CAPL seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking services and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

Singapore: This report is distributed in Singapore by CLSA Singapore Pte Ltd to institutional investors, accredited investors or expert investors (each as defined under the Financial Advisers Regulations) only. Singapore recipients should contact CLSA Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore 048624, Tel: +65 6416 7888, in respect of any matters arising from, or in connection with, the analysis or report. By virtue of your status as an institutional investor, accredited investor or expert investor, CLSA Singapore Pte Ltd is exempted from complying with certain requirements under the Financial Advisers Act 2001, the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder (as disclosed in Part C of the Securities Dealing Services - Singapore Annex of the CLSA terms of business), in respect of any financial advisory services that CLSA Singapore Pte Ltd may provide to ydick(DR) 042/11/2022.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas, LLC. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA (except CLSA Americas, LLC) solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas, LLC. However, the delivery of this research



report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas, LLC.

The United Kingdom: This document is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is disseminated in the UK by CLSA (UK) and directed at persons having professional experience in matters relating to investments, as defined in the relevant applicable local regulations. Any investment activity to which it relates is only available to such persons. If you do not have

professional experience in matters relating to investments you should not rely on this document. Where research material is compiled by UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules in the UK such material is prepared and intended as substantive research material. CLSA (UK) is authorised and regulated by the Financial Conduct Authority.

The European Economic Area ('EEA"): research is distributed by CLSA Europe BV, authorised and regulated by the Netherlands Authority for Financial Markets.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this report may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the report in the respective jurisdictions.© 2023 CLSA and/or CL Securities Taiwan Co., Ltd. ("CLST").